



savyonDIAGNOSTICS

Member of the gamida Diagnostics Division

savvy^{gen} STI CT/NG/TV

REF 618-01

Test kit for 48 determinations




≤ - 20°C

For Professional Use Only **IVD**



Savyon® Diagnostics Ltd.
3 Habosem St. Ashdod 7761003
ISRAEL
Tel.: +(972).8.8562920
Fax: +(972).8.8523176
E-mail: support@savyondiagnosics.com

CE 0483



**European Authorized
Representative: Obelis s.a.**
Boulevard Général Wahis 53
1030 Brussels, BELGIUM
Tel: +(32) 2. 732.59.54
Fax: +(32) 2.732.60.03
E-Mail : mail@obelis.net



Intended Use

The Savvygen™ STI CT/NG/TV allows the qualitative detection of *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG) and *Trichomonas vaginalis* (TV) by Real-Time PCR in urine or from a vaginal swab specimen. The test is intended as an aid in the diagnosis of *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG) and/or *Trichomonas vaginalis* (TV) infections, in both symptomatic and asymptomatic individuals.

For *in-vitro* professional diagnostic use.

Background

According to the World Health Organization (WHO) more than 340 million new cases of sexually transmitted bacterial and protozoan infections occur throughout the world every year (1). Sexually transmitted diseases (STDs) also known as Sexually Transmitted Infections (STIs) consist of diseases that are spread primarily through person-to-person sexual contact. STIs represent a significant public health concern. Although many STIs remain asymptomatic or do not exhibit clear and distinctive symptoms, such infections may result in acute symptoms as well as other severe delayed consequences such as infertility, ectopic pregnancy, cervical cancer and death (2; 3). These diseases are caused by more than 30 pathogenic viruses, bacteria and parasites (1). Furthermore, infection by STDs increases substantially the potential of acquiring or transmitting human immunodeficiency virus HIV. Such interaction could account for 40% or more of HIV transmissions (1; 3). The Savvygen™ STI CT/NG/TV was developed in order to detect three of the most common sexually transmitted pathogens- *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG), *Trichomonas vaginalis* (TV).

Chlamydia trachomatis – is found only in humans. This bacterium is a major infectious cause of human genital and eye disease and the most commonly diagnosed STI. *C. trachomatis* infection is one of the most common sexually transmitted infections worldwide. *C. trachomatis* is also known as a "silent epidemic" due to the fact that about three quarters of infected women and about half of infected men have no symptoms. If symptoms do occur, they usually appear within 1 to 3 weeks after exposure. *C. trachomatis* is easily treated with antibiotics, but can lead to serious long-term health problems such as chronic pelvic pain, infertility, and potentially fatal ectopic pregnancy if left untreated. Infected pregnant women can potentially pass *C. trachomatis* to the newborn during pregnancy, causing eye or lung infections. *C. trachomatis* can be safely treated during pregnancy by taking proper antibiotics (4, 5).

Neisseria gonorrhoeae - also known as gonococci or gonococcus is a species of Gram negative coffee bean-shaped diplococci bacteria. *N. gonorrhoeae* is the second most common bacterial STI after *C. trachomatis*. Around 10% of infected males and 80% of infected females are asymptomatic. Women with gonorrhoeae are at risk of developing serious complications such as pelvic inflammatory disease (PID), regardless the presence or severity of the symptoms. This disease can affect the woman's ability to give birth if left untreated as well as increase the risk of ectopic pregnancy. Transmission of the bacterium to the baby can result in a gonococcal eye infection, which must be treated with antibiotics to avoid blindness. Successful treatment of gonorrhoeae will avoid recurrence; however will not prevent cases of re-infections (6, 7). Antibiotic-resistance of *N. gonorrhoeae* has been noted by epidemiologists from the early 1940s. *N. gonorrhoeae* that is resistant to the penicillin family of antibiotics is treated by ceftriaxone (a third-generation cephalosporin).

Trichomonas vaginalis – is an anaerobic, flagellated protozoan parasite and the causative agent of trichomoniasis. It is the most common pathogenic protozoan infection of humans in industrialized countries. Infection rates in men and women are similar, however, while women are usually symptomatic, infections in men are typically asymptomatic. Transmission usually occurs via direct skin-to-skin contact with an infected individual most often through sexual intercourse. The WHO has estimated that 160 million cases of infections are acquired annually worldwide. Pregnant women with trichomoniasis are in risk of delivering premature or low birth weight babies (6, 8).



Principles of the Test

The Savvygen™ STI CT/NG/TV is a ready-to use test which contains all the necessary reagents for Real-Time PCR assay. The test is designed for the diagnosis of *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and/or *Trichomonas vaginalis* in human urine specimens or vaginal swabs to aid in the assessment of infections caused by these sexually transmitted bacteria.

The Savvygen™ STI CT/NG/TV test is based on amplification of highly specific conserved fragments in the *pbpB* and *hct* genes of *Chlamydia trachomatis* (CT), the *orf1* gene of *Neisseria gonorrhoeae* (NG) and the *18S* gene of *Trichomonas vaginalis* (TV). Following extraction of bacterial DNA the fragments are amplified by Taq DNA in Polymerase Chain Reaction (PCR). The assay is based on the 5'→3' exonuclease activity of Taq DNA Polymerase (figure 1). A fluorophore/quencher dual-labeled probe is annealing to an internal specific sequence. Upon primer elongation, Taq DNA Polymerase displaces and hydrolyzes the probe, thus releasing and activating the fluorophore. The presence of the pathogen is detected by an increase in the observed fluorescence during the reaction. The resulting increase in fluorescence signal is proportional to the amount of amplified product in the sample and detected by the real-time PCR thermocycler.




Figure 1. Principle of the Savvygen™ assay

The optical channels used for multiplexed detection of the amplified fragments are outlined in table 1 below:

Table 1. Savvygen™ STI CT/NG/TV target and optical channel detection;

Name	LightCycler ®96	Bio-Rad CFX96	ABI 7500 Real-Time PCR
CT	FAM	FAM	FAM
NG	HEX	Cal orang 560	VIC
TV	Cy5	Quasar 670	Cy5
Internal Control	Red610	Cal Red610	ROX

*In ABI 7500 Real-Time PCR, ROX channel as a reference dye is un-marked



Materials/ Reagents Provided

Product Description	Contents
Savvygen™ STI CT/NG/TV 48 reactions. Cat.# 618-01	3x Savvygen CT/NG/TV Master Mix* vials (264 µL each)
	1x Savvygen CT/NG/TV positive Control (50 µL each)

* Master-mix vial contains all reagents required for the amplification reaction

Additional Equipment and Material Required

- **Reagents**

- DNA extraction kit.
 - Ultrapure water (for negative control)

- **Disposables**

- Micropipettes (0.5-20 µL, 20-200 µL).
 - Powder-free disposal gloves
 - PCR instrument plate or strips

- **Instruments**

- Centrifuge for 1.5 mL tube.
 - Vortex.
 - Real-Time PCR thermocycler (see table 2A+2B for compatible RT-PCRs).

Note: Savvygen™ STI CT/NG/TV has been validated on the: Bio-Rad CFX96 Touch™ Real-Time PCR Detection System, Roche LightCycler®96 Real-Time PCR System and 7500 Real-Time PCR System

Table 2A. Compatible Real-Time PCR instruments (Low-Profile)

Bio-Rad	Applied Biosystems
CFX96 Touch™ Real-Time PCR Detection System	7500 Fast Real-Time PCR System
Roche	7500 Fast Dx Real-Time PCR System
LightCycler®480 Real-Time PCR System	QuantStudio™ 12K Flex 96-well Fast
LightCycler®96 Real-Time PCR System	QuantStudio™ 6 Flex 96-well Fast
Agilent Technologies	QuantStudio™ 7 Flex 96-well Fast
AriaMx Real-Time PCR System	QuantStudio™ 5 Real-Time PCR System
DNA-Technology	ViiA™ 7 Fast Real-Time PCR System
DTlite Real-Time PCR System	Cepheid
DT prime Real-Time Detection Thermal Cycler	SmartCycler®*
	Qiagen
	Rotor-Gen® Q*



Table 2B. Compatible Real-Time PCR instrument (High-Profile)

Bio-Rad	Applied Biosystems
<i>CFX96 Touch Deep Well Real-Time PCR Detection System</i>	<i>7500 Real-Time PCR System</i>
<i>iCycler iQ Real-Time PCR Detection System</i>	<i>QuantStudio™ 12K Flex 96-well</i>
<i>iCycler iQ 5 Real-Time PCR Detection System</i>	<i>QuantStudio™ 6 Flex 96-well</i>
DNA-Technology	<i>QuantStudio™ 7 Flex 96-well</i>
<i>DTlite Real-Time PCR System</i>	<i>QuantStudio™ 5 Real-Time PCR System</i>
<i>DT prime Real-Time Detection Thermal Cycler</i>	<i>ViiA™ 7 Real-Time PCR System</i>
Stratagene /Agilent Technologies	Qiagen
<i>Mx3000P™ Real-Time PCR System</i>	<i>Rotor-Gen® Q*</i>
<i>Mx3005P™ Real-Time PCR System</i>	Cepheid
Analytik Jena Biometra	<i>SmartCycler®*</i>
<i>TOptical</i>	Abbot
<i>qTOWER 2.0</i>	<i>Abbot m2000 Real-Time System</i>

Transport and Kit Storage

The Savvygen™ STI CT/NG/TV *kit* should be transported and stored at ≤20°C. All components are stable under recommended storage conditions until the expiry date as stated on the label.

Note: Each Master-mix vial is good for up to 3 freeze/thaw cycles. After 3 uses the vial should be disposed according to Good Laboratory Practice guidelines.

Precautions

Amplification technologies can amplify target nucleic acid sequences over a billion-fold, providing an efficient way for detecting very low target concentrations. Care must be taken to avoid contamination of samples with target nucleic acids from other samples, or amplicons from previous amplifications. The following are recommendations to help contamination control:

1. Separate pre-amplification from post-amplification steps. Use separate locations for pre- and post-amplifications. Use dedicated lab equipment for each stage. Prepare samples in a laminar flow hood using dedicated equipment. Set up the post-amplification area in a low-traffic area as possible.
2. The laboratory process must be one-directional. It should start in the Extraction Area and then move to the Amplification and Detection Areas. Do not return samples, equipment and reagents to the area in which the previous step was performed.
3. Use disposable containers, barrier pipette tips, bench pads, and gloves. Avoid washable lab wear.
4. Use a diluted bleach solution (0.2% sodium hypochlorite) to treat waste from the post-amplification and detection areas, as the waste contains amplicons. Use the bleach solution to wipe down equipment and bench areas, as well as to treat drains used for disposal of liquid waste.
5. Use negative controls to detect possible contaminations during the reaction setup. If reagent contamination is detected, dispose the suspected reagents.
6. Do not use reagents after the expiration date stated on the box.
7. Specimens must be treated as potential infectives as well as all reagents and materials that had been exposed to the samples. All these should be handled in the same manner as an infectious agent. Take necessary precautions during the collection, storage, treatment and disposal of samples.



Test Procedure

Specimen Collection, Processing and DNA Extraction

In order to obtain an adequate sample, the procedure for sample collection must be followed closely and according to the manufacturer's instructions. The specimens should be transported as fast as possible and stored at the indicated temperature conditions.

Nucleic Acid (NA) Extraction: for pre-treatment and NA isolation of the specimens, it is recommended to use an appropriate DNA extraction kit according to manufacturer's protocol. NA Extraction may be carried out manually or automatically using commercially available extraction kits. Several extraction systems were validated for this kit including:

- Savyon STI Extraction kit (Savyon Diagnostics Cat#651-01; 652-01)
- QIAamp DNA mini kit (Qiagen)
- Nimbus IVD (Hamilton)
- NucliSENS® easyMag® (Biomérieux)

Programming the Real-Time PCR Instrument

Thermal profile

Set your thermocycler to the following conditions below (table 3):

Table 3. PCR program profile for the Savvygen™ CT/NG/TV

Step	Temperature (°C)	Time	Cycles
Polymerase activation	95	1 min	1
Denaturation	95	5 sec	45
Annealing/Extension	60 *	30 sec	

* Set the fluorescence data collection during the extension step (*) through the FAM, Red610, Cy5, and HEX, JOE or VIC channels.

Note: Set the reaction volume to 20µl.

Fluorescence reading

Select the detection channels on your Real-Time PCR instrument as appear below:

Name	LightCycler®96	Bio-Rad CFX96	ABI 7500 Real-Time PCR
CT	FAM	FAM	FAM
NG	HEX	Cal orang 560	VIC
TV	Cy5	Quasar 670	Cy5
Internal Control	Red610	Cal Red610	ROX

*In ABI 7500 Real-Time PCR, ROX channel as a reference dye is un-marked

Preparing reaction wells

Calculate the number of required reactions including samples and controls. It is highly recommended to run at least one positive and one negative control per run.

1. Thaw the Master mix tube.
2. Before use, mix by inverting the tube 2-3 times and then do a short spin down. **Do not vortex!**



Adding reagents, samples and controls into the reaction plate / strip

3. Pipette 15 µL of the Master mix into each well.
4. Pipette 5 µL of DNA sample into each sample well.
5. Pipette 5 µL of the Positive Control into the positive control well.
6. Pipette 5 µL of Negative Control (Ultra-pure Water; not provided) into each negative control well.
7. Cover the wells with the suitable caps/seal. Spin down briefly if needed.

Performing PCR

8. Place the strips/plate in the Real-Time PCR instrument.
9. Start the run.

The fluorescence detection channels of common Real-Time PCR Thermocyclers are specified in Table 4.

Table 4: Detection fluorescence channels of different Real-Time PCR systems

RT- PCR THERMOCYCLER	System Detection channels	Savvygen probes channels	Remarks
Roche LightCycler® 96 or LightCycler®480II	465/510	FAM	Color Compensation is required only for LC480 system
	533/580	HEX	
	533/610	ROX	
	618/660	Cy5	
Applied Biosystems ABI 7500 fast	FAM	FAM	Passive reference option ROX is not mark
	VIC	HEX	
	ROX	ROX	
	Cy5	Cy5	
Bio-Rad CFX96™	FAM	FAM	
	HEX	HEX	
	ROX	ROX	
	Cy5	Cy5	
Agilent AriaMx	FAM	FAM	
	HEX	HEX	
	ROX	ROX	
	Cy5	Cy5	
DNA-Technology DTlite / DTprime	FAM	FAM	
	HEX	HEX	
	ROX	ROX	
	Cy5	Cy5	
Smartcyler® Cepheid	Channel 1	FAM	
	Channel 2	HEX	
	Channel 3	ROX	
	Channel 4	Cy5	
Abbott m2000rt	FAM	FAM	
	HEX	HEX	
	ROX	ROX	
	Cy5	Cy5	
Rotor-Gene®Q Qiagen	Green	FAM	
	Yellow	HEX	
	Orange	ROX	
	Red	Cy5	



Analysis of results

Interpretation of results (table 5) can be automatically performed if programmed by the user using the RT-PCR instrument software following manufacturer's instructions. It is required to run assay controls (positive and negative controls) in each run to validate the reaction.

Note: The positive controls used in each run, must show an amplification curve of the tested targets which validates the reaction while the negative control well should demonstrate an absence of signal (except internal control target).

Positive sample- A sample is considered a positive for the target in the presence of amplification curve signal.

Negative sample- A sample is considered negative for the target if there is no evidence of amplification curve signal in the detection system and the internal control is positive.

Internal Control- The internal control must show an amplification curve, which verifies the correct function of the amplification mix. It should be noted that the detection of internal control may not be necessary in case of positive results in one or more of the pathogens. .

Positive control- The positive control used in each run is expected to show an amplification curve for the 3 pathogens which validates the reaction.

Negative control- The negative control included in each run is expected to show no amplification curve signal for the 3 STI bacteria which validates the reaction.

Invalid run- The assay should be considered as invalid and a new run should be performed if there is a signal of amplification curve for one of the pathogens in the negative control well or absence of amplification curve signal in the positive control well.

Note: If an amplification curve for the internal control is not shown, it may be due to PCR inhibitors. In such case the sample should be retested by dilution of the original sample 1:10. Alternatively it is recommended to repeat the nucleic acid extraction.

Table 5. Interpretation of results.

<i>T. vaginalis</i> (Cy5)	<i>C.trachomatis</i> (FAM)	<i>N. gonorrhoeae</i> (HEX)	Internal Control (Red610)	Negative Control	Positive Control	Interpretation
POS	POS	POS	POS / NEG	NEG	POS	<i>T. Vaginalis, C.trachomatis</i> and <i>N. gonorrhoeae</i> Positive
NEG	NEG	NEG	POS	NEG	POS	<i>T. Vaginalis, C.trachomatis</i> and <i>N. gonorrhoeae</i> Negative
POS	NEG	NEG	POS / NEG	NEG	POS	<i>T. Vaginalis</i> Positive , <i>C.trachomatis</i> and <i>N.</i> <i>gonorrhoeae</i> Negative
NEG	POS	NEG	POS / NEG	NEG	POS	<i>C.trachomatis</i> Positive , <i>T.</i> <i>Vaginalis</i> and <i>N. gonorrhoeae</i> Negative
NEG	NEG	POS	POS / NEG	NEG	POS	<i>N. gonorrhoeae</i> Positive , <i>T.</i> <i>Vaginalis</i> and <i>C.trachomatis</i> Negative
POS	POS	NEG	POS / NEG	NEG	POS	<i>T. Vaginalis</i> and <i>C.trachomatis</i> Positive , <i>N. gonorrhoeae</i> Negative



NEG	POS	POS	POS / NEG	NEG	POS	<i>C.trachomatis</i> and <i>N. gonorrhoeae</i> Positive , <i>T. Vaginalis</i> Negative
POS	NEG	POS	POS / NEG	NEG	POS	<i>T. Vaginalis</i> and <i>N. gonorrhoeae</i> Positive , <i>C.trachomatis</i> Negative
POS	POS	POS	POS	POS	POS	Invalid Run
NEG	NEG	NEG	NEG	NEG	NEG	Invalid Run
NEG/POS	NEG/POS	NEG/POS	POS	NEG	NEG	Invalid Run

POS: presence of amplification curve signal

NEG: No amplification curve signal

Limitations of the Test

- All results should be used and interpreted in the context of a full clinical evaluation as an aid in the diagnosis of sexually transmitted infections.
- This test was only validated for urine and/or vaginal swabs.
- Error results may occur due to improper sample collection, handling, storage, technical error, sample mix-up, or the amount of organisms in the sample which is below the analytical sensitivity of the test.
- The presence of PCR inhibitors may cause invalid results.
- A false positive result with other targets may derive from contamination by PCR products from previous testing.
- As with all PCR-based *in-vitro* diagnostic tests, extremely low levels of target below the analytical sensitivity of the assay may be detected, but results may not be reproducible.
- If a certain sample result is Invalid then the sample should be repeated starting from DNA extraction stage.

Quality Control

In order to confirm the appropriate performance of the molecular diagnostic technique, an Internal Control (IC) is included in each reaction. In addition, positive and negative controls are included in each assay to enable correct interpretation of the results.

Performance Characteristics

Clinical sensitivity and specificity

Clinical performance characteristics of the Savvygen™ STI CT/NG/TV were assessed by evaluation of retrospective (frozen) specimens (DNA, urine and swabs). These specimens are consisted of residual anonymized urine and swabs collected and processed in various clinical laboratories, which were verified by CE approved molecular methods. The performance of the Savvygen™ STI CT/NG/TV test is presented in table 6:



Table 6. Results interpretation

Pathogen	Positive Agreement		Specificity	
	TP/ (TP+FN)	Percent	TN/ (TN+FP)	Percent
<i>Chlamydia trachomatis</i>	169/170	99%	206/206	100%
<i>Neisseria gonorrhoeae</i>	52/52	100%	324/324	100%
<i>Trichomonas vaginalis</i>	73/73	100%	303/303	100%

TP- True Positive; TN- True Negative; FP- False Positive; FN- False Negative

Analytical sensitivity and specificity

Analytical sensitivity

Serial dilutions of samples containing a plasmid with the targets sequences were tested in three different batches in consecutive experiments. Six replicates of each dilution were tested per target (pathogen) and the limit of detection (LOD) was set accordingly to the last dilution in which all replicates were identified. LOD for all the pathogens in the assay is presented in Table 7:

Table 7: LOD (copy/reaction) of the Savvygen™ CT/NG/TV

Pathogen	Copy No./Reaction
<i>Chlamydia trachomatis</i>	14
<i>Neisseria gonorrhoeae</i>	21
<i>Trichomonas vaginalis</i>	35

Analytical specificity

In order to detect possible cross-reactions of the Savvygen™ STI CT/NG/TV, samples positive for potential cross-reactive pathogens were tested. None of the tested pathogens revealed a positive result.

Table 8: Cross-Reactivity experiment

	<i>Chlamydia trachomatis</i>	<i>Neisseria gonorrhoeae</i>	<i>Trichomonas vaginalis</i>
<i>Neisseria lactamica</i>	-	-	-
<i>Dientamoeba fragilis</i>	-	-	-
<i>Campylobacter jejuni</i>	-	-	-
<i>candida albicans</i>	-	-	-
<i>Yersinia type 4</i>	-	-	-
<i>Yersinia type 2</i>	-	-	-
<i>Human papillomavirus type 18</i>	-	-	-
<i>Human papillomavirus type 16</i>	-	-	-
<i>Chlamydophila pneumoniae</i>	-	-	-
<i>Neisseria meningitidis</i>	-	-	-
<i>Enterococcus faecium</i>	-	-	-
<i>Enterococcus faecalis</i>	-	-	-
<i>Klebsiella pneumoniae carbapenemase</i>	-	-	-
<i>Enterobacter aerogenes</i>	-	-	-
<i>Enterobacter cloacae</i>	-	-	-













<i>Enterococcus avium</i>	-	-	-
<i>Staphylococcus aureus</i>	-	-	-
<i>sallmonela spp.</i>	-	-	-
<i>Klebsiella pneumoniae</i>	-	-	-
<i>Chlamydia trachomatis</i>	+	-	-
<i>Herpes simplex virus type 2</i>	-	-	-
<i>Mycoplasma hominis</i>	-	-	-
<i>Ureaplasma parvum</i>	-	-	-
<i>Trichomonas vaginalis</i>	-	-	+
<i>Ureaplasma urealyticum</i>	-	-	-
<i>Neisseria gonorrhoeae</i>	-	+	-
<i>Clamydia psitachi</i>	-	-	-
<i>Herpes Simplex Virus type 2</i>	-	-	-

Bibliography

1. Organization, World Health. Global Strategy for Prevention and Control of Sexually transmitted Infections: 2006-2015: breaking the chain of transmission. 2007.
2. Eng TR, Butler WT. The Hidden Epidemic: confronting sexually transmitted diseases. Institute of Medicine (US). Washington (DC): National Academy Press, 1997. pp. 41-49.
3. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2010. 2011.
4. Current Methods of Laboratory Diagnosis of *Chlamydia trachomatis* Infections. Black, Carolyn M. 1, 1997, Clinical Microbiology Reviews , Vol. 10, pp. 164-180.
5. Observations from the CDC: The Silent Epidemic of *Chlamydia trachomatis*: The Urgent Need for Detection and Treatment in Women. Walsh, Cathleen, Anderson, Linda A and Kathleen, Irwin. 4, 2000, Journal of Women's Health & Gender-Based Medicine, Vol. 9, pp. 339-343.
6. Workowski, Kimberly. Sexually Transmitted Diseases Treatment Guideline. Centers for Disease Control and Prevention. 2010. MMWR. RR-12.
7. Diagnosis and Treatment of *Neisseria gonorrhoeae* Infections. Miller, Karl E. 10, 2006, Am Fam Physician, Vol. 73, pp. 1779-1784.
8. Trichomoniasis. Schwebke, Jane R and Donald, Burgess. 4, 2004, Clinical Microbiology Reviews, Vol. 17, pp. 794-803.

Symbols for IVD Components and Reagents

 Manufacturer	 Use by	 For <i>in vitro</i> diagnostic use only
 Lot number	 Temperature limitation	 Consult instructions for use
 Catalogue number	 Contains sufficient for <n> test	 Buffer (sample diluent)
 Keep Dry		

CFX™ and IQ5™ are registered trademarks of Bio-Rad Laboratories.

ABI®, QuantStudio™, StepOne Plus™ and ViiA™ are registered trademarks of Thermo Fisher Scientific Inc.

LightCycler® is a registered trademark of Roche.

Mx3000P™ and Mx3005™ are registered trademarks of Agilent Technologies.

Rotor-Gene® Q is a registered trademark of Qiagen.

SmartCycler® is a registered trademark of Cepheid